BRAF and melanoma: Surprisingly, we saw that the decreases in proteolytic shedding had only quantitatively minor predicted effects on lysate levels in the cell line models tested here, although it has previously been shown to serve as a biomarker for poor patient progression free survival in melanoma patients treated with Mek and Braf inhibitors.34 Further study in systems with higher levels of shed protein will be needed to gain a better understanding of if and when proteolytic shedding is a major contributor to drug resistance.